Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study

ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program. Results During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported. Conclusions Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-11-14
DOI
https://doi.org/10.1002/jha2.70454
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study

Thorsten Braun, Maël Heiblig, Delphine Lebon, Anne Vekhoff et al.
eJHaem
Acute Myeloid Leukemia Research
article

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study

Thorsten Braun, Maël Heiblig, Delphine Lebon, Anne Vekhoff, Cécile Pautas, Emmanuel Raffoux, Juliette Lambert, Karïn Gogat, Alberto Santagostino
article en

Abstract

ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program. Results During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported. Conclusions Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551

eJHaemVol. 7(6)
Centre Hospitalier Universitaire Henri-Mondor (FR), Sorbonne Université (FR), Université Sorbonne Paris Nord (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Antoine (FR), Hôpital Lyon Sud (FR), Pfizer (France) (FR), Centre Hospitalier de Troyes (FR), Hôpital Avicenne (FR), Hôpitaux Universitaires Henri-Mondor (FR), Hôpital Saint-Louis (FR), Centre Hospitalier de Versailles (FR)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon